Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load

AIDS Research and Human Retroviruses

Volumn 22, Issue 8, 2006, Pages 788-795

  Cummins Jr , James E ^a,e   Christensen, Logan ^a   Lennox, Jeffery L ^b   Bush, Timothy J ^a   Wu, Zhiwei ^c   Malamud, Daniel ^c   Evans Strickfaden, Tammy ^a   Siddig, Aladin ^a   Caliendo, Angela M ^b   Hart, Clyde E ^a   Dezzutti, Charlene S ^a,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; CATHEPSIN D; CYTOKINE; GLYCOPROTEIN; GLYCOPROTEIN GP 340; INTERLEUKIN 1BETA; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHEMOKINE; IMMUNOLOGIC FACTOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LEUKOCYTE; MAJOR CLINICAL STUDY; MUCOSAL IMMUNITY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TEST STRIP; URINALYSIS; VAGINA MUCOSA; VAGINAL LAVAGE; VIRUS LOAD; VIRUS SHEDDING; ADOLESCENT; ANALYSIS OF VARIANCE; BLOOD; CHI SQUARE DISTRIBUTION; IMMUNOLOGY; MIDDLE AGED; VAGINA; VIREMIA; VIROLOGY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHEMOKINES; CHI-SQUARE DISTRIBUTION; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; IMMUNOLOGIC FACTORS; MIDDLE AGED; RNA, VIRAL; VAGINA; VIRAL LOAD; VIREMIA; VIRUS SHEDDING;

EID: 33748747491     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.788     Document Type: Article

References (53)

1. Joint United Nations Program of HIV/AIDS: AIDS Epidemic Update, December 2002.
2. Downs AM and De Vincenzi I: Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11: 388-395.
3. Gray RH, Wawer MJ, Brookmeyer R, et al.: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
4. Leynaert B, Downs AM, and de Vincenzi I: Heterosexual transmission of human immunodeficiency virus: Variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998;148:88-96.
5. Padian NS, Shiboski SC, Glass SO, and Vittinghoff E: Heterosexual transmission of human immunodeficiency virus (HIV) in northem California: Results from a ten-year study. Am J Epidemiol 1997;146:350-357.
6. Peterman TA, Stonebumer RL, Allen JR, Jaffe HW, and Curran JW: Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988;259:55-58.
7. Pedraza MA, del Romero J, Roldan F, et al.: Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999;21:120-125.
8. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929.
9. Fleming DT and Wasserheit JN: From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999:75:3-17.
10. Gray RH, Li X, Wawer MJ, et al.: Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004;189:1209-1215.
11. Serwadda D, Gray RH, Sewankambo NK, et al.: Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: A nested case-control study in Rakai, Uganda. J Infect Dis 2003;188:1492-1497.
12. Goulston C, McFarland W, and Katzenstein D: Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Infect Dis 1998;177:1100-1103.
13. Hart CE, Lennox JL, Pratt-Palmore M, et al.: Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999;179:871-882.
14. Iversen AK, Larsen AR, Jensen T, et al.: Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis 1998;177:1214-1220.
15. Pilcher CD, Price MA, Hoffman IF, et al.: Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004;18:517-524.
16. Spinillo A, Debiaggi M, Zara F, Maserati R, Polatti F, and De Santolo A: Factors associated with nucleic acids related to human immunodeficiency virus type 1 in cervico-vaginal secretions. Br J Obstet Gynaecol 2001;108:634-641.
17. Coombs RW, Wright DJ, Reichelderfer PS, et al.: Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: Implications for applying measurements to individual women. J Infect Dis 2001;184:1187-1191.
18. Debiaggi M, Zara F, Spinillo A, et al.: Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001;20:91-96.
19. Villanueva JM, Ellerbrock TV, Lennox JL, et al.: The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis 2002;185:170-177.
20. Lawn SD, Subbarao S, Wright TC Jr, et al.: Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000;181:1950-1956.
21. Ghys PD, Fransen K, Diallo MO, et al.: The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS 1997;11:F85-93.
22. McClelland RS, Wang CC, Mandaliya K, et al.: Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001;15:105-110.
23. Spinillo A, Debiaggi M, Zara F, Maserati R, Polatti F, and De Santolo A: Factors associated with nucleic acids related to human immunodeficiency virus type 1 in cervico-vaginal secretions. Br J Obstet Gynecol 2001;108:634-641.
24. Wright TC Jr, Subbarao S, Ellerbrock TV, et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001;184:279-285.
25. Iversen AK, Attermann J, Gerstoft J, Fugger L, Mullins JI, and Skinhoj P: Longitudinal and cross-sectional studies of HIV-1 RNA and DNA loads in blood and the female genital tract. Eur J Obstet Gynecol Reprod Biol 2004;117:227-235.
26. Zara F, Nappi RE, Brerra R, Migliavacca R, Maserati R, and Spinillo A: Markers of local immunity in cervico-vaginal secretions of HIV infected women: Implications for HIV shedding. Sex Transm Infect 2004;80:108-112.
27. Ward PA and Lentsch AB: Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 2002;234-235:225-228.
28. Ward PP, Uribe-Luna S, and Conneely OM: Lactoferrin and host defense. Biochem Cell Biol 2002;80:95-102.
29. El Messaoudi K, Thiry L, Van Tieghem N, et al.: HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions. AIDS 1999;13:333-339.
30. Hashemi FB, Mollenhauer J, Madsen LD, et al.: Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS 2001;15:441-449.
31. Moriuchi M and Moriuchi H: A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 2001;166:4231-4236.
32. Wu Z, Van Ryk D, Davis C, et al.: Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses 2003;19:201-209.
33. Shugars DC, Sauls DL, and Weinberg JB: Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis 1997;3(Suppl. 1):S70-72.
34. Guenthner PC and Hart CE: Quantitative, competitive, PCR assay for HIV-1 using a microplate-based detection system. BioTechniques 1998;24:810-816.
35. Wu Z, Golub E, Abrams WR, and Malamud D: gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction. AIDS Res Hum Retroviruses 2004;20:600-607.
36. Donato R: Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999;1450:191-231.
37. Ryckman C, Robichaud GA, Roy J, Cantin R, Tremblay MJ, and Tessier PA: HIV-1 transcription and virus production are both accentuated by the proinflammatory myeloid-related proteins in human CD4+ T lymphocytes. J Immunol 2002;169:3307-3313.
38. Hiscott J, Kwon H, and Genin P: Hostile takeovers: Viral appropriation of the NF-kappaB pathway. J Clin Invest 2001;107:143-151.
39. Vorland LH: Lactoferrin: A multifunctional glycoprotein. Apmis 1999;107:971-981.
40. Kang W and Reid KB: DMBT1, a regulator of mucosal homeostasis through the linking of mucosal defense and regeneration? FEBS Lett 2003;540:21-25.
41. Swart PJ, Kuipers ME, Smit C, et al.: Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996;12:769-775.
42. Hiemstra PS: Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 2002;30:116-120.
43. Poll G, Bressler P, Kinter A, et al.: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990;172:151-158.
44. Poli G, Kinter A, Justement JS, et al.: Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-785.
45. Crouch SP, Slater KJ, and Fletcher J: Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992;80:235-240.
46. Mork G, Schjerven H, Mangschau L, Soyland E, and Brandtzaeg P: Proinflammatory cytokines upregulate expression of calprotectin (L1 protein, MRP-8/MRP-14) in cultured human keratinocytes. Br J Dermatol 2003;149:484-491.
47. Spear GT, Sha BE, Saarloos MN, et al.: Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: Correlation with other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:454-459.
48. Iversen AK, Fugger L, Eugen-Olsen J, et al.: Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J Infect Dis 1998;178:1334-1342.
49. Cohn MA, Frankel SS, Rugpao S, et al.: Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J Infect Dis 2001;184:410-417.
50. Niruthisard S, Roddy RE, and Chutivongse S: The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991;18:176-179.
51. Stafford MK, Ward H, Flanagan A, et al.: Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects. J Acquir Immune Defic Syndr Human Retrovirol 1998;17:327-331.
52. Van Damme L, Ramjee G, Alary M, et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-977.
53. Fichorova RN, Tucker LD, and Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184:418-428.